Trial
NCT01111448
Temsirolimus in Myelodysplastic Syndrome (MDS)
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Technische Universität Dresden
Collaborators
Wyeth is now a wholly owned subsidiary of Pfizer
Condition
Myelodysplastic Syndrome
Intervention
Temsirolimus
Why stopped
Unfavourable Risk-Benefit-Ratio
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-02-13